MedTrace Logo

A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

NCT00168441 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2011-05-30

No results posted yet for this study

Summary

4-month study including a 30-day baseline phase

Conditions

  • Postherpetic Neuralgia

Interventions

DRUG

Botulinum Toxin Type A

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2005-06-30
Completion
2005-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168441 on ClinicalTrials.gov